keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/29774314/surgical-highlights-from-the-40-th-san-antonio-breast-cancer-symposium-5-9-december-2017-san-antonio-texas
#1
Enver Özkurt
This year San Antonio Breast Cancer Symposium (SABCS) celebrated its 40th anniversary. As in the past years, this year's conference was held in Henry B. Gonzalez Convention Centre, San Antonio, Texas, on 5-9 December 2017. The conference highlighted many different topic on breast cancer including basic science, translational research, local therapies, systemic therapies, survivorship, early clinical trials, and surgical topics. Even though SABCS evolved towards basic science and systemic therapy based manner in recent years, there were some important topics about local therapies and surgical approach...
April 2018: European Journal of Breast Health
https://www.readbyqxmd.com/read/29764245/pembrolizumab-versus-the-standard-of-care-for-relapsed-and-refractory-classical-hodgkin-s-lymphoma-progressing-after-brentuximab-vedotin-an-indirect-treatment-comparison
#2
Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante, Arun Balakumaran
BACKGROUND: There is significant unmet need among patients with relapsed and refractory classical Hodgkin's lymphoma (RRcHL) who have failed multiple lines of therapy, including brentuximab vedotin (BV). Pembrolizumab, an immune checkpoint inhibitor, is one possible treatment solution for this population. RESEARCH METHODS: The objective of this study was to compare progression-free survival (PFS) with standard of care (SOC) versus pembrolizumab in previously BV treated RRcHL patients...
May 15, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29740841/innovation-in-eating-disorders-research-and-practice-expanding-our-community-and-perspectives-at-the-2018-international-conference-on-eating-disorders-editorial-to-accompany-ijed-virtual-issue-in-honor-of-the-2018-international-conference-on-eating-disorders
#3
Phillippa C Diedrichs, Kristin M von Ranson, Jennifer J Thomas
OBJECTIVE: This virtual issue of the International Journal of Eating Disorders (IJED) highlights the excellent and innovative research and practice discussed at the 2018 International Conference on Eating Disorders held in Chicago, Illinois, USA. METHOD AND RESULTS: The virtual issue contains a series of articles recently published in IJED, which we have curated to reflect and expand on the insights delivered during the conference keynote and plenary presentations...
May 8, 2018: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/29705098/contemporary-concepts-in-hernia-prevention-selected-proceedings-from-the-2017-international-symposium-on-prevention-of-incisional-hernias
#4
Hobart W Harris, William H Hope, Gina Adrales, Dana K Andersen, Eva B Deerenberg, Holger Diener, Gregory Dumanian, Barbora East, John P Fischer, Miguel A Garcia Ureña, George J Gibeily, Birgitta M Hansson, Pilar Hernández-Granados, Michael C Hiles, Johannes Jeekel, Howard Levinson, Manuel Lopez-Cano, Filip Muysoms, José Antonio Pereira, Michel Prudhomme, Archana Ramaswamy, Cesare Stabilini, Jared Torkington, Silvia Valverde, David M Young
Incisional hernia is a frequent complication of midline laparotomy and enterostomal creation and is associated with high morbidity, decreased quality of life, and high costs. The International Symposium on Incisional Hernia Prevention was held October 19-20, 2017, at the InterContinental Hotel in San Francisco, CA, hosted by the Department of Surgery, University of California, San Francisco. One hundred and three attendees included general and plastic surgeons from 9 countries, including principal participants for several of the seminal studies in the field...
April 25, 2018: Surgery
https://www.readbyqxmd.com/read/29700739/keynote-symposium
#5
(no author information available yet)
No abstract text is available yet for this article.
April 26, 2018: In Vitro Cellular & Developmental Biology. Animal
https://www.readbyqxmd.com/read/29685882/baseline-tumor-size-is-an-independent-prognostic-factor-for-overall-survival-in-patients-with-melanoma-treated-with-pembrolizumab
#6
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard F Kefford, Wen-Jen Hwu, Jedd D Wolchok, Anthony Michael Joshua, Antoni Ribas, F Stephen Hodi, Omid Hamid, Caroline Robert, Adil I Daud, Roxana S Dronca, Peter Hersey, Jeffrey S Weber, Amita Patnaik, Dinesh P de Alwis, Andrea M Perrone, Jin Zhang, Soonmo Peter Kang, Scot W Ebbinghaus, Keaven M Anderson, Tara Gangadhar
PURPOSE: To assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827). EXPERIMENTAL DESIGN: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS)...
April 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29682899/generalization-and-representativeness-of-phase-iii-immune-checkpoint-blockade-trials-in-non-small-cell-lung-cancer
#7
Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
BACKGROUND: Strict eligibility criteria for patient enrollment in phase III trials raise questions regarding generalization to ineligible patients. We evaluated whether pivotal phase III trials of immune checkpoint blockades (ICBs) represent the overall population of non-small cell lung cancer (NSCLC) patients. METHODS: We reviewed the inclusion and exclusion criteria of three phase III trials (CheckMate057, CheckMate017, and KEYNOTE-010). Stage IIIB or IV NSCLC patients diagnosed from 2011 to 2013 at Seoul National University Hospital (cohort 1) were reviewed...
April 22, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29682332/gender-and-outcomes-in-non-small-cell-lung-cancer-an-old-prognostic-variable-comes-back-for-targeted-therapy-and-immunotherapy
#8
Joseph A Pinto, Carlos S Vallejos, Luis E Raez, Luis A Mas, Rossana Ruiz, Junior S Torres-Roman, Zaida Morante, Jhajaira M Araujo, Henry L Gómez, Alfredo Aguilar, Denisse Bretel, Claudio J Flores, Christian Rolfo
Background: There are well-known differences in gender outcome in non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the gender influence in the outcome of patients with NSCLC treated with targeted therapy and immunotherapy. Methods: We performed a series of meta-analysis to compare the gender outcome in the routine setting for overall survival and progression-free survival (PFS) in phase III randomised clinical trials comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, LUX-lung 6, EURTAC, ENSURE and WTJOG); ALK inhibitors versus chemotherapy (ASCEND 4, ASCEND 5, PROFILE 1014 and NCT009323893) and anti-PD1 checkpoint inhibitors versus chemotherapy (CheckMate 017, CheckMate 026, CheckMate 057, KEYNOTE 010 and KEYNOTE 024)...
2018: ESMO Open
https://www.readbyqxmd.com/read/29674442/first-report-of-dramatic-tumor-responses-with-ramucirumab-and-paclitaxel-after-progression-on-pembrolizumab-in-two-cases-of-metastatic-gastroesophageal-adenocarcinoma
#9
Sakti Chakrabarti, Haidong Dong, Harshita R Paripati, Helen J Ross, Harry H Yoon
Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29658856/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer
#10
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell, Susanna Y-S Cheng, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M Catherine Pietanza, Marina C Garassino
Background First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial. Methods In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy...
April 16, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29652545/strategies-for-optimal-cardiovascular-aging
#11
Douglas R Seals, Vienna E Brunt, Matthew J Rossman
This review summarizes the opening keynote presentation overview of the American Physiological Society conference on Cardiovascular Aging: New Frontiers and Old Friends held in Westminster, CO, in August 2017. Age is the primary risk factor for cardiovascular diseases (CVD). Without effective intervention, increased numbers of older adults in the future will translate to greater prevalence of CVD and related disorders. Advancing age increases the risk of CVD partly via direct effects on the heart and through increases in blood pressure; however, much of the risk is mediated by arterial dysfunction, including large elastic artery stiffening and both macro- and micro-vascular endothelial dysfunction...
April 13, 2018: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/29611460/conference-report-6th-annual-international-symposium-on-regenerative-rehabilitation
#12
M Terry Loghmani, Joseph A Roche
The 6th International Symposium on Regenerative Rehabilitation, hosted by the Alliance for Regenerative Rehabilitation Research and Training (AR3 T), included a preconference meeting of institutional representatives of the International Consortium of Regenerative Rehabilitation, keynote talks from distinguished scientists, platform and poster presentations from experts and trainees, panel discussions and postconference workshops. The following priorities were identified: increasing rigor in basic, preclinical and clinical studies, especially the use of better controls; developing better outcome measures for preclinical and clinical trials; focusing on developing more tissue-based interventions versus cell-based interventions; including regenerative rehabilitation in curricula of professional programs like occupational and physical therapy; and developing better instruments to quantify rehabilitative interventions...
April 3, 2018: Regenerative Medicine
https://www.readbyqxmd.com/read/29590008/health-related-quality-of-life-analysis-from-keynote-045-a-phase-iii-study-of-pembrolizumab-versus-chemotherapy-for-previously-treated-advanced-urothelial-cancer
#13
David J Vaughn, Joaquim Bellmunt, Yves Fradet, Jae Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I Quinn, Stephane Culine, Cora N Sternberg, Yabing Mai, Haojie Li, Rodolfo F Perini, Dean F Bajorin, Ronald de Wit
Purpose In the phase III KEYNOTE-045 study ( ClinicalTrials.gov identifier: NCT02256436), pembrolizumab significantly prolonged overall survival compared with investigator's choice of chemotherapy in patients with previously treated advanced urothelial cancer. Here, we report the results of health-related quality-of-life (HRQoL) analyses from the KEYNOTE-045 trial. Patients and Methods Patients were randomly assigned 1:1 to pembrolizumab 200 mg or investigator's choice of docetaxel 75 mg/m2 , paclitaxel 175 mg/m2 , or vinflunine 320 mg/m2 administered intravenously every 3 weeks...
March 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29576265/cost-effectiveness-of-pembrolizumab-in-second-line-advanced-bladder-cancer
#14
Michal Sarfaty, Peter S Hall, Kelvin K W Chan, Kiran Virik, Moshe Leshno, Noa Gordon, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A Goldstein
BACKGROUND: Immune-modulating drugs have recently been introduced to the second-line setting of advanced bladder cancer. Pembrolizumab increases overall survival and is associated with less toxicity compared with chemotherapy in this setting based on the Keynote 045 study. The high cost of immunotherapy necessitates an assessment of its value by considering both efficacy and cost. OBJECTIVE: To estimate the cost-effectiveness of pembrolizumab for the second-line treatment of advanced bladder cancer from the perspective of payers in multiple countries...
March 22, 2018: European Urology
https://www.readbyqxmd.com/read/29573218/understanding-environmental-contributions-to-autism-causal-concepts-and-the-state-of-science
#15
REVIEW
Irva Hertz-Picciotto, Rebecca J Schmidt, Paula Krakowiak
The complexity of neurodevelopment, the rapidity of early neurogenesis, and over 100 years of research identifying environmental influences on neurodevelopment serve as backdrop to understanding factors that influence risk and severity of autism spectrum disorder (ASD). This Keynote Lecture, delivered at the May 2016 annual meeting of the International Society for Autism Research, describes concepts of causation, outlines the trajectory of research on nongenetic factors beginning in the 1960s, and briefly reviews the current state of this science...
March 23, 2018: Autism Research: Official Journal of the International Society for Autism Research
https://www.readbyqxmd.com/read/29569462/conceptualizing-obesity-as-a-chronic-disease-an-interview-with-dr-arya-sharma
#16
Arya M Sharma, Donna L Goodwin, Janice Causgrove Dunn
Dr. Arya M. Sharma challenges the conventional wisdom of relying simply on "lifestyle" approaches involving exercise, diet, and behavioral interventions for managing obesity, suggesting that people living with obesity should receive comprehensive medical interventions similar to the approach taken for other chronic diseases such as Type 2 diabetes or hypertension. He purports that the stigma-inducing focus on self-failing (e.g., coping through food, laziness, lack of self-regulation) does not address biological processes that make obesity a lifelong problem for which there is no easy solution...
March 23, 2018: Adapted Physical Activity Quarterly: APAQ
https://www.readbyqxmd.com/read/29559561/safety-and-antitumor-activity-of-pembrolizumab-in-patients-with-estrogen-receptor%C3%A2-positive-human-epidermal-growth-factor-receptor-2%C3%A2-negative-advanced-breast-cancer
#17
Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A Ott, Sarina A Piha-Paul, Phillipe L Bedard, Jasgit Sachev, Christophe Le Tourneau, Emilie M J van Brummelen, Andreea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R Tan
PURPOSE: We investigated the safety and antitumor activity of the anti-programmed death 1 monoclonal antibody pembrolizumab in patients with estrogen receptor‒positive (ER+)/human epidermal growth factor receptor 2-negative (HER2- ) advanced breast cancer with programmed death ligand 1‒positive (PD-L1‒positive) tumors in the phase Ib open-label, multicohort KEYNOTE-028 (NCT02054806) study. EXPERIMENTAL DESIGN: Patients with ER+/HER2- advanced breast cancer with PD-L1‒positive tumors (combined positive score ≥1) received pembrolizumab (10 mg/kg every 2 weeks) up to 2 years or until confirmed progression/intolerable toxicity...
March 20, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29556919/recent-advances-in-medical-therapy-for-metastatic-urothelial-cancer
#18
Takeshi Yuasa, Shinji Urakami, Junji Yonese
Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. Very recently, in 2017, pembrolizumab, a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1, was approved as a second-line treatment to be used after platina-based chemotherapy for metastatic urothelial cancer in Japan. Based on its promising anti-tumor efficacy and manageable safety profile as demonstrated in the phase III KEYNOTE-045 trial, pembrolizumab therapy is expected to be rapidly introduced for treating metastatic urothelial cancer in clinical practice...
March 20, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29550584/proceedings-of-the-2017-annual-meeting-of-the-fetal-alcohol-spectrum-disorders-study-group
#19
REVIEW
Jeffrey R Wozniak, Anna Y Klintsova, Derek A Hamilton, Sandra M Mooney
The 2017 Fetal Alcohol Spectrum Disorders Study Group (FASDSG) meeting was titled "Prenatal alcohol exposure in the context of multiple factors affecting brain development." The theme was reflected in the interactions between members of the Teratology Society and the FASDSG this year. The first keynote speaker, Elaine Faustman, Ph.D., was a liaison between the societies and spoke about systems biology and the multiple genetic and environmental influences on development. The second keynote speaker, Rebecca Knickmeyer, Ph...
November 1, 2017: Alcohol
https://www.readbyqxmd.com/read/29543932/safety-and-efficacy-of-pembrolizumab-monotherapy-in-patients-with-previously-treated-advanced-gastric-and-gastroesophageal-junction-cancer-phase-2-clinical-keynote-059-trial
#20
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A Wainberg, Daniel V Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H Ko, Geoffrey Ku, Philip Philip, Peter C Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Rosales, Rita P Dalal, Harry H Yoon
Importance: Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective: To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. Design, Setting, and Participants: In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016...
March 15, 2018: JAMA Oncology
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"